Celestial develops mRNA vaccines and therapeutics for infectious diseases and cancer. Their technology aims to provide novel preventative and treatment options through advanced mRNA delivery.
Funding
$725K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many infectious diseases, rare diseases, and cancers lack effective preventative and therapeutic options, creating a significant unmet need for novel medical interventions. Traditional vaccine and therapeutic development can be slow and may not always elicit a sufficient immune response or provide durable protection.
Solution
Celestial Therapeutics is developing next-generation mRNA vaccines and therapeutics, as well as dual modal antivirals/anti-inflammatories, for the prevention and treatment of infectious diseases, rare diseases, and cancers. The company leverages two proprietary technology platforms: a Stellar mRNA platform licensed from Harvard University, and a lipid platform based on pulmonary surfactant lipids. The Stellar mRNA platform encodes short, noncoding immunostimulatory RNA (isRNA) sequences within mRNA to enhance innate immune responses and antigen presentation. The lipid platform utilizes an endogenous phospholipid, CT-02, which has demonstrated antiviral and anti-inflammatory properties against respiratory viruses.
Target Audience
The primary target audience includes patients and healthcare providers seeking innovative preventative and therapeutic options for infectious diseases, rare diseases, and cancers.
Features
- Stellar mRNA platform for enhanced immunostimulation and streamlined vaccine development
- Lipid platform based on pulmonary surfactant lipids with dual antiviral and anti-inflammatory properties
- CT-02, a lead antiviral drug candidate targeting RSV infections
- Development of mRNA vaccines and therapeutics for infectious diseases, rare diseases, and cancers
- Streamlined vaccine development pipeline to reduce "needle-to-needle" time
- Focus on diseases and conditions with significant unmet medical needs